The V2 receptor antagonist tolvaptan counteracts proliferation and invasivity in human cancer cells

被引：0
|
作者：
G. Marroncini
C. Anceschi
L. Naldi
B. Fibbi
F. Baldanzi
M. Maggi
A. Peri
机构：
[1] AOU Careggi,Pituitary Diseases and Sodium Alterations Unit
[2] University of Florence,Endocrinology, Department of Experimental and Clinical Biomedical Sciences “Mario Serio”
[3] AOU Careggi,undefined
来源：
Journal of Endocrinological Investigation | 2022年 / 45卷
关键词：
Tolvaptan; AVP receptors; Hyponatremia; Cancer; SIAD;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1693 / 1708
页数：15
相关论文
共 50 条
  • [1] The V2 receptor antagonist tolvaptan counteracts proliferation and invasivity in human cancer cells
    Marroncini, G.
    Anceschi, C.
    Naldi, L.
    Fibbi, B.
    Baldanzi, F.
    Maggi, M.
    Peri, A.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2022, 45 (09) : 1693 - 1708
  • [2] Tolvaptan, Vasopressin V2 Receptor Antagonist
    Inomata, Takayuki
    JOURNAL OF CARDIAC FAILURE, 2010, 16 (09) : S135 - S135
  • [3] Effects of tolvaptan, an oral vasopressin V2 receptor antagonist, in hyponatremia
    Madias, Nicolaos E.
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2007, 50 (02) : 184 - 187
  • [4] Tolvaptan, an oral vasopressin V2 receptor antagonist for heart failure?
    Greenberg, Arthur
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2007, 50 (06) : 904 - 907
  • [5] Nonclinical pharmacokinetics of a new nonpeptide V2 receptor antagonist, tolvaptan
    Furukawa M.
    Umehara K.
    Kashiyama E.
    Cardiovascular Drugs and Therapy, 2011, 25 (Suppl 1) : S83 - S89
  • [6] Efficacy of vasopressin V2 receptor antagonist tolvaptan in treatment of hepatic edema
    Hiramine, Yasunari
    Uto, Hirofumi
    Imamura, Yasushi
    Hiwaki, Takuya
    Kure, Takeshi
    Ijuin, Sho
    Oda, Kohei
    Mawatari, Seiichi
    Kumagai, Kotaro
    Tokunaga, Koki
    Higashi, Hirofumi
    Kanetsuki, Ichiro
    Kubozono, Osamu
    Maenohara, Shigeho
    Ido, Akio
    HEPATOLOGY RESEARCH, 2017, 47 (06) : 542 - 557
  • [7] Determinants of Urine Volume in ADPKD Patients Using the Vasopressin V2 Receptor Antagonist Tolvaptan
    Kramers, Bart J.
    van Gastel, Maatje D. A.
    Boertien, Wendy E.
    Meijer, Esther
    Gansevoort, Ron T.
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2019, 73 (03) : 354 - 362
  • [8] V2 receptor antagonism with tolvaptan in heart failure
    Costello-Boerrigter, Lisa C.
    Boerrigter, Guido
    Burnett, John C., Jr.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2007, 16 (10) : 1639 - 1647
  • [9] DETERMINANTS OF URINE VOLUME IN ADPKD-PATIENTS USING THE VASOPRESSIN V2 RECEPTOR ANTAGONIST TOLVAPTAN
    Kramers, Bart
    Heida, Judith
    Boertien, Wendy
    van Gastel, Maatje
    Meijer, Esther
    Gansevoort, Ron
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2018, 33
  • [10] Structural basis of tolvaptan binding to the vasopressin V2 receptor
    Liu, Hong-li
    Zhong, Hai-yang
    Zhang, Yi-xiao
    Xue, Hua-rui
    Zhang, Zheng-shuo
    Fu, Ke-quan
    Cao, Xu-dong
    Xiong, Xiao-chun
    Guo, Dong
    ACTA PHARMACOLOGICA SINICA, 2024, 45 (11) : 2441 - 2449
12345